



10 April 2024

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – Successful completion institutional component of Entitlement Offer

SomnoMed Limited (**SomnoMed** or **Company**) is today pleased to announce the successful completion of the institutional component (**Institutional Entitlement Offer**) of its 1 for 1.01 accelerated non-renounceable entitlement offer of new fully paid ordinary shares (**New Shares**) in the Company (**Entitlement Offer**).

The Institutional Entitlement Offer closed on Tuesday, 9 April 2024.

Approximately 27.5 million New Shares will be issued to successful applicants under the Institutional Entitlement Offer at an issue price of \$0.21 per New Share (**Offer Price**), raising an aggregate of approximately A\$5.8 million. The Institutional Entitlement Offer had strong support from existing domestic and international institutional shareholders with a take-up rate of approximately 70.6%.

The shortfall of A\$1.7 million (8.1 million shares) from the Institutional Entitlement Offer has been placed to certain new and existing institutional investors. No shortfall shares were allocated to the sub-underwriter, TDM Growth Partners Pty Ltd (**TDM**) (a major shareholder of the Company).

The use of proceeds of the Entitlement Offer was outlined in the Company's Prospectus released on Tuesday, 9 April 2024, and included investment into manufacturing capacity initiatives, a cost out program and paydown of the Epsilon Direct Lending debt facility. As a result of the successful completion of the Institutional Entitlement Offer, SomnoMed's ordinary shares (**Shares**) will recommence normal trading on an ex-entitlement basis from the opening of the market on Wednesday, 10 April 2024.

New Shares issued pursuant to the Institutional Entitlement Offer will rank equally with existing Shares on issue with effect from their date of issue. New Shares subscribed for under the Institutional Entitlement Offer are expected to be settled on Monday, 15 April 2024 and to be issued and commence trading on the ASX on Wednesday, 17 April 2024.

Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will raise up to a further approximately \$16.8 million.

The Retail Entitlement Offer is available to shareholders whose address is in Australia and New Zealand as recorded with the Company's share registry as at 7.00pm (Sydney, Australia time) on Thursday, 11 April 2024 (**Record Date**) (**Eligible Retail Shareholders**).

Eligible Retail Shareholders are being invited to subscribe for 1 Share for every 1.01 Shares held on the Record Date at the Offer Price of \$0.21 per Share. The offer ratio and offer price for Shares under the Retail Entitlement Offer are the same as for the Institutional Entitlement Offer. Eligible Retail Shareholders who take up their entitlement in full under the Retail Entitlement Offer may elect to apply for that number of additional New Shares in excess of their Entitlement under an oversubscription facility (subject to the Company's absolute discretion to scale back applications).

The Retail Entitlement Offer will open on Tuesday, 16 April 2024 and close at 5.00pm (Sydney, Australia time) on Wednesday, 1 May 2024 (unless extended or withdrawn).

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the prospectus and accompanying personalised entitlement and acceptance form, which are expected to be dispatched on Tuesday, 16 April 2024. A copy of the prospectus was lodged with ASX on Tuesday, 9 April 2024.

Key Dates

Key dates for the Entitlement Offer are as follows:

Event	Date (2024)
Prospectus lodged, Institutional Entitlement Offer opens	Tuesday, 9 April
Institutional Entitlement Offer closes	Tuesday, 9 April
Suspension lifted, trading resumes on an ex-entitlement basis	Wednesday, 10 April
Record date for the Entitlement Offer	7:00pm (AEST) on Thursday, 11 April
Settlement of shares issued under the Institutional Entitlement Offer	Monday, 15 April
Retail Entitlement Offer opens, prospectus and acceptance forms issued	Tuesday, 16 April
Allotment of New Shares issued under the Institutional Entitlement Offer	Tuesday, 16 April
Normal trading of New Shares issued under the Institutional Entitlement Offer	Wednesday, 17 April
Retail Entitlement Offer closes	5:00pm (AEST) on Wednesday, 1 May
Settlement of Retail Entitlement Offer	Tuesday, 7 May
Allotment of New Shares issued under the Retail Entitlement Offer	Wednesday, 8 May
Normal trading of New Shares issued under the Retail Entitlement Offer	Thursday, 9 May

The above timetable is indicative only and subject to change.

If you have any questions in relation to the prospectus and accompanying personalised entitlement and acceptance form or the Entitlement Offer, please contact the Offer Information line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia). For other questions, you should consult your broker, solicitor, accountant, financial adviser or other professional adviser.

Wilsons Corporate Finance Limited is acting as sole lead manager, bookrunner and underwriter to the Entitlement Offer.

TDM and other existing institutional and non-institutional shareholders appointed as sub-underwriters intend to subscribe for any shortfall of the Retail Entitlement Offer.



Terry Flitcroft
Company Secretary
SomnoMed Limited

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 860,000 patients in 28 countries. For further information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold in the Entitlement Offer have not been, and will not be, registered under the United States Securities Act of 1933 (the **U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States.

Accordingly, the New Shares may not be offered or sold to persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in SomnoMed.